DexCom (NASDAQ:DXCM) Rating Lowered to Hold at Baird R W

Baird R W cut shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a hold rating in a report published on Friday morning, Zacks.com reports.

A number of other research analysts have also issued reports on DXCM. Canaccord Genuity Group reissued a buy rating and set a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a buy rating in a research note on Wednesday, April 3rd. Robert W. Baird lowered shares of DexCom from an outperform rating to a neutral rating and reduced their target price for the company from $161.00 to $80.00 in a research note on Friday. JPMorgan Chase & Co. lowered shares of DexCom from an overweight rating to a neutral rating and reduced their price target for the stock from $145.00 to $75.00 in a research note on Friday. Finally, Oppenheimer reduced their price target on shares of DexCom from $150.00 to $115.00 and set an outperform rating for the company in a research note on Friday. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average target price of $111.50.

DexCom Trading Up 5.4 %

NASDAQ DXCM opened at $67.48 on Friday. DexCom has a one year low of $62.34 and a one year high of $142.00. The company has a 50-day simple moving average of $114.02 and a 200-day simple moving average of $123.33. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The firm has a market capitalization of $27.04 billion, a PE ratio of 43.54, a price-to-earnings-growth ratio of 1.58 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS. On average, equities analysts forecast that DexCom will post 1.76 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold 3,483 shares of company stock worth $401,450 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the 2nd quarter valued at approximately $25,000. DSM Capital Partners LLC bought a new stake in DexCom in the fourth quarter worth approximately $28,000. Crewe Advisors LLC bought a new stake in DexCom in the first quarter worth approximately $29,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. Finally, Riverview Trust Co bought a new stake in DexCom in the first quarter worth approximately $32,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.